SCHEMBL4808264

SCHEMBL4808264

CC(C)OC(=O)c1ccc(C2(C(=O)Cl)CCCCC2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.49
CA1 P00915 3/20 0.49
CA2 P00918 3/20 0.49
CA7 P43166 3/20 0.49
CA9 Q16790 3/20 0.49
CA14 Q9ULX7 3/20 0.49
PDCD1 Q15116 1/20 0.45
CD274 Q9NZQ7 1/20 0.45
CYP4F2 P78329 1/20 0.43
CYP4A11 Q02928 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
NPSR1 Q6W5P4 3/20 0.42
GAA P10253 1/20 0.42
ALDH1A1 P00352 3/20 0.40
LMNA P02545 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
HTT P42858 1/20 0.40
HDAC4 P56524 2/20 0.40
MAPT P10636 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4804658 0.87 AKR1C1 (0.51) CA12CA1CA2CA7CA9
SCHEMBL4814166 0.84 SMN1; SMN2 (0.47) CA12CA1CA2CA7CA9
SCHEMBL4813835 0.81 CA12 (0.44) CA12CA1CA2CA7CA9
SCHEMBL4806678 0.80 SMN1; SMN2 (0.42) CA12CA1CA2CA9CA14
SCHEMBL4817363 0.77 AKR1C1 (0.47) SMN1; SMN2HDAC4TSHRALOX15MEN1
SCHEMBL4815384 0.76 HDAC1 (0.46) SMN1; SMN2ALDH1A1LMNANPC1RAB9A
SCHEMBL4810246 0.75 MAPT (0.47) SMN1; SMN2NPSR1ALDH1A1LMNAHDAC4
SCHEMBL4807202 0.74 CYP3A4 (0.56) SMN1; SMN2NPSR1GAAALDH1A1LMNA
SCHEMBL8256047 0.74 CA12 (0.56) CA12CA1CA2CA7CA9
SCHEMBL701832 0.74 CA12 (0.83) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7465719-B2 Carbamic acid compounds comprising an ester or ketone linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2008-12-16 US disclosed
US-20060058282-A1 Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors TOPOTARGET UK LIMITED (GB) 2006-03-16 US disclosed
EP-1583736-A1 CARBAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS TopoTarget UK Limited (GB) 2005-10-12 EP disclosed
WO-2004065354-A1 CARBAMIC ACID COMPOUNDS COMPRISING AN ESTER OR KETONE LINKAGE AS HDAC INHIBITORS TOPOTARGET UK LIMITED (GB) 2004-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058282-A1 Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors HDAC1, HDAC7, HDAC11 CA12 379/4885CA1 151/4885CA2 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.